-DOCSTART- -X- O
Influenza -X- _ O
is -X- _ O
a -X- _ O
disease -X- _ O
that -X- _ O
poses -X- _ O
a -X- _ O
significant -X- _ O
health -X- _ O
burden -X- _ O
worldwide. -X- _ O
Vaccination -X- _ O
is -X- _ O
the -X- _ O
best -X- _ O
way -X- _ O
to -X- _ O
prevent -X- _ O
influenza -X- _ B-Patient
virus -X- _ I-Patient
infections. -X- _ I-Patient
However -X- _ O
, -X- _ O
conventional -X- _ B-Intervention
vaccines -X- _ I-Intervention
are -X- _ O
only -X- _ O
effective -X- _ O
for -X- _ O
a -X- _ O
short -X- _ O
period -X- _ O
of -X- _ O
time -X- _ O
due -X- _ O
to -X- _ O
the -X- _ O
propensity -X- _ O
of -X- _ O
influenza -X- _ B-Patient
viruses -X- _ I-Patient
to -X- _ O
undergo -X- _ O
antigenic -X- _ O
drift -X- _ O
and -X- _ O
antigenic -X- _ O
shift. -X- _ O
The -X- _ O
efficacy -X- _ O
of -X- _ O
these -X- _ O
vaccines -X- _ O
is -X- _ O
uncertain -X- _ O
from -X- _ O
year-to-year -X- _ O
due -X- _ O
to -X- _ O
potential -X- _ O
mismatch -X- _ O
between -X- _ O
the -X- _ O
circulating -X- _ O
viruses -X- _ O
and -X- _ O
vaccine -X- _ O
strains -X- _ O
, -X- _ O
and -X- _ O
mutations -X- _ O
arising -X- _ O
due -X- _ O
to -X- _ O
egg -X- _ O
adaptation. -X- _ O
Subsequently -X- _ O
, -X- _ O
the -X- _ O
inability -X- _ O
to -X- _ O
store -X- _ O
these -X- _ O
vaccines -X- _ O
long-term -X- _ O
and -X- _ O
vaccine -X- _ O
shortages -X- _ O
are -X- _ O
challenges -X- _ O
that -X- _ O
need -X- _ O
to -X- _ O
be -X- _ O
overcome. -X- _ O
Conventional -X- _ B-Intervention
vaccines -X- _ I-Intervention
also -X- _ O
have -X- _ O
variable -X- _ O
efficacies -X- _ O
for -X- _ O
certain -X- _ O
populations -X- _ O
, -X- _ O
including -X- _ O
the -X- _ O
young -X- _ O
, -X- _ O
old -X- _ O
, -X- _ O
and -X- _ O
immunocompromised. -X- _ O
This -X- _ O
warrants -X- _ O
for -X- _ O
diverse -X- _ O
efficacious -X- _ O
vaccine -X- _ O
developmental -X- _ O
approaches -X- _ O
, -X- _ O
involving -X- _ O
both -X- _ O
active -X- _ O
and -X- _ O
passive -X- _ O
immunization. -X- _ O
As -X- _ O
opposed -X- _ O
to -X- _ O
active -X- _ B-Comparison
immunization -X- _ I-Comparison
platforms -X- _ I-Comparison
( -X- _ O
requiring -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
whole -X- _ O
or -X- _ O
portions -X- _ O
of -X- _ O
pathogens -X- _ O
as -X- _ O
vaccines -X- _ O
) -X- _ O
, -X- _ O
the -X- _ O
rapidly -X- _ O
developing -X- _ O
passive -X- _ O
immunization -X- _ O
involves -X- _ O
administration -X- _ O
of -X- _ O
either -X- _ O
pathogen-specific -X- _ O
or -X- _ O
broadly -X- _ O
acting -X- _ O
antibodies -X- _ O
against -X- _ O
a -X- _ O
kind -X- _ O
or -X- _ O
class -X- _ O
of -X- _ O
pathogens -X- _ O
as -X- _ O
a -X- _ O
treatment -X- _ O
to -X- _ O
corresponding -X- _ O
acute -X- _ O
infection. -X- _ O
Several -X- _ B-Outcome
antibodies -X- _ I-Outcome
with -X- _ I-Outcome
broadly -X- _ I-Outcome
acting -X- _ I-Outcome
capacities -X- _ I-Outcome
have -X- _ I-Outcome
been -X- _ I-Outcome
discovered -X- _ I-Outcome
that -X- _ I-Outcome
may -X- _ I-Outcome
serve -X- _ I-Outcome
as -X- _ I-Outcome
means -X- _ I-Outcome
to -X- _ I-Outcome
suppress -X- _ I-Outcome
influenza -X- _ I-Outcome
viral -X- _ I-Outcome
infection -X- _ I-Outcome
and -X- _ I-Outcome
allow -X- _ I-Outcome
the -X- _ I-Outcome
process -X- _ I-Outcome
of -X- _ I-Outcome
natural -X- _ I-Outcome
immunity -X- _ I-Outcome
to -X- _ I-Outcome
engage -X- _ I-Outcome
opsonized -X- _ I-Outcome
pathogens -X- _ I-Outcome
whilst -X- _ I-Outcome
boosting -X- _ I-Outcome
immune -X- _ I-Outcome
system -X- _ I-Outcome
by -X- _ I-Outcome
antibody-dependent -X- _ I-Outcome
mechanisms -X- _ I-Outcome
that -X- _ I-Outcome
bridge -X- _ I-Outcome
the -X- _ I-Outcome
innate -X- _ I-Outcome
and -X- _ I-Outcome
adaptive -X- _ I-Outcome
arms. -X- _ I-Outcome
By -X- _ O
that -X- _ O
; -X- _ O
passive -X- _ B-Intervention
immunotherapeutics -X- _ I-Intervention
approach -X- _ O
assumes -X- _ O
a -X- _ O
robust -X- _ O
tool -X- _ O
that -X- _ O
could -X- _ O
aid -X- _ O
control -X- _ O
of -X- _ O
influenza -X- _ B-Patient
viruses. -X- _ I-Patient
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
comment -X- _ O
on -X- _ O
some -X- _ O
improvements -X- _ O
in -X- _ O
influenza -X- _ O
management -X- _ O
and -X- _ O
promising -X- _ O
vaccine -X- _ O
development -X- _ O
platforms -X- _ O
with -X- _ O
an -X- _ O
emphasis -X- _ O
on -X- _ O
the -X- _ O
protective -X- _ O
capacity -X- _ O
of -X- _ O
passive -X- _ B-Intervention
immunotherapeutics -X- _ I-Intervention
especially -X- _ O
when -X- _ O
coupled -X- _ O
with -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
antivirals -X- _ B-Comparison
in -X- _ O
the -X- _ O
management -X- _ O
of -X- _ O
influenza -X- _ O
infection -X- _ O
. -X- _ O

